PRO-542
Also known as: CD4-IgG2, PRO542, Tetrameric CD4-IgG2
Source PRO-542 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
PRO‑542 (also called CD4‑IgG2 or tetrameric CD4‑IgG2) is an investigational recombinant fusion protein designed to block the first step of HIV‑1 entry. By mimicking the CD4 receptor, it binds the viral envelope glycoprotein gp120, preventing attachment of the virus to host CD4+ cells. It is being studied as a novel entry inhibitor to complement existing antiretroviral regimens, but it has not yet progressed to approved clinical use.
Mechanism of Action
PRO‑542 is a CD4‑IgG2 immunoadhesin that presents four CD4 domains fused to an IgG2 Fc fragment. The CD4 moieties bind the gp120 subunit of the HIV‑1 envelope, sterically blocking the interaction between viral gp120 and the host CD4 receptor. This prevents the conformational changes required for coreceptor (CCR5/CXCR4) engagement and membrane fusion. The Fc region may also engage immune effector pathways, although the primary antiviral effect is through direct inhibition of viral attachment.
What the Research Shows
The literature describes PRO‑542 as a prototype CD4‑attachment inhibitor under investigation for HIV treatment. Review articles list it among emerging entry inhibitors and note its classification as a CD4‑receptor inhibitor. In vitro studies reported that PRO‑542 synergizes with the fusion inhibitor enfuvirtide (T20), achieving more than ten‑fold greater inhibition of R5, X4, and dual‑tropic strains than either agent alone. No human clinical trial data are presented in the abstracts; the compound remains in the pre‑clinical or early investigational phase, with its safety and efficacy in patients still uncharacterized.
Reported Benefits
In vitro data suggest PRO‑542 can block multiple HIV‑1 tropisms (R5, X4, and R5X4) and enhances the antiviral activity of existing entry inhibitors such as T20. By targeting the attachment step, it offers a mechanistically distinct option that could be combined with reverse‑transcriptase or protease inhibitors to broaden regimen potency and potentially overcome resistance to current drugs.
Limitations of the Evidence
Evidence for PRO‑542 is limited to laboratory studies; no human efficacy or safety data have been reported. Its developmental status is investigational, and there is no information on pharmacokinetics, dosing, or resistance patterns. The potential for viral escape, immunogenicity of the fusion protein, and manufacturing challenges remain unaddressed, making its clinical utility uncertain at present.
Safety Considerations
The abstracts provide no data on adverse events or toxicity in humans. As a recombinant protein, PRO‑542 could provoke immune reactions, including antibody formation against the Fc region, but this has not been evaluated. Until pre‑clinical and clinical safety studies are completed, the safety profile remains unknown, and caution is warranted for any future use.
How It Is Administered
PRO‑542 is formulated as a recombinant protein intended for parenteral delivery. The structured data list intravenous and subcutaneous routes as possible administration pathways. Specific dosing regimens, infusion rates, or formulation details are not described in the available literature.
Routes of Administration
Goals & Uses
- Pediatric HIV-1 treatmentAntiviral TherapyLow
- Salvage therapy for treatment-experienced HIV patientsAntiviral TherapyLow
- HIV-1 entry inhibitionMechanism Based Viral SuppressionModerate
- HIV-1 viral load reductionAntiviral EfficacyModerate
Contraindications
- Hypersensitivity to CD4-IgG2 or IgG2-based biologicsImmunologicHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Immunogenicity / anti-drug antibodiesImmunologicUncommon
Drug Interactions
- Antiretroviral agents (combination ART)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients < 2 yearsAgeRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorization granted by EMA
- United StatesInvestigationalStudied under IND; Phase I/II completed; never approved by FDA
- United KingdomInvestigationalNo regulatory approval in the UK
PRO-542 was studied in Phase I/II clinical trials. It was never submitted for or granted regulatory approval by FDA, EMA, or other agencies. It remains an investigational compound. Developed by Progenics Pharmaceuticals.
Evidence & Sources
- Journal ArticleModerateStarr-Spires LD, Collman RG2002-01-01T00:00:00.000000Z
- Journal ArticleModerateGhosh RK, Ghosh SM, Chawla S2011-01-01T00:00:00.000000Z
- Journal ArticleModerateReeves JD, Piefer AJ2005-01-01T00:00:00.000000Z
- Journal ArticleModerateKnutson KL2002-01-01T00:00:00.000000Z
- Journal ArticleModerateVermeire K, Schols D2003-01-01T00:00:00.000000Z
- Journal ArticleModerateGulick RM2003-01-01T00:00:00.000000Z
Frequently Asked Questions
What stage of development is PRO‑542 in?
PRO‑542 is an investigational entry inhibitor that has only been studied in vitro. The available abstracts do not report any completed human clinical trials, so it remains in the early research phase.
How does PRO‑542 differ from other HIV entry inhibitors?
Unlike fusion inhibitors that block membrane merging, PRO‑542 mimics the CD4 receptor and directly prevents the virus from attaching to host cells. This distinct mechanism targets the first step of entry rather than later steps.
Has PRO‑542 been shown to work against drug‑resistant HIV?
The published data show activity against multiple viral tropisms in laboratory assays, but no studies have examined its efficacy against clinically resistant HIV strains.
Are there any known side effects of PRO‑542?
No safety or toxicity information is provided in the cited literature. As a recombinant protein, potential immune reactions are a theoretical concern, but they have not been evaluated.
Can PRO‑542 be used together with existing antiretroviral drugs?
In vitro experiments demonstrated synergistic inhibition when PRO‑542 was combined with the fusion inhibitor enfuvirtide (T20). However, clinical data on combination use are lacking.
What is PRO-542?
PRO‑542 (also called CD4‑IgG2 or tetrameric CD4‑IgG2) is an investigational recombinant fusion protein designed to block the first step of HIV‑1 entry. By mimicking the CD4 receptor, it binds the viral envelope glycoprotein gp120, preventing attachment of the virus to host CD4+ cells. It is being studied as a novel entry inhibitor to complement existing antiretroviral regimens, but it has not yet progressed to approved clinical use.
What is PRO-542 used for?
PRO-542 is educationally associated with: Pediatric HIV-1 treatment, Salvage therapy for treatment-experienced HIV patients, HIV-1 entry inhibition, HIV-1 viral load reduction. Educational only — not medical advice.
How is PRO-542 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of PRO-542?
Reported adverse effects include: Flu-like symptoms, Injection site reactions, Headache, Immunogenicity / anti-drug antibodies. This list is not exhaustive — consult a qualified clinician.
Who should avoid PRO-542?
Recorded contraindications: Hypersensitivity to CD4-IgG2 or IgG2-based biologics. Consult a qualified clinician before use.